Psychopharmacology

Psychedelics Psychedelic Research Psychedelic Substances Clinical Trials Hallucinogens Rapid-Acting Antidepressants Cannabis Research Drug Safety Research Studies Caffeine Research

OHSU Multisite Study Finds Mental Health Gains and Low Serious Harms From Oregon’s Regulated Psilocybin Services

The results offer early real-world evidence to guide policy and research on regulated psilocybin access.

Stories older than 24h

Psilocybin Therapy Puts Most Veterans With Treatment‑Resistant PTSD Into Remission

High‑Dose Psilocybin Sessions Produced Temporary Gains in an Elderly Alzheimer’s Patient

THC Intoxication Broadly Disrupts Memory, Heightens False Recall, Study Finds

Five-Year Follow-Up Finds 67% Remission After Psilocybin-Assisted Therapy

Single 100-Microgram Dose of LSD Drug Eased GAD for 12 Weeks in JAMA Trial

First Morning Coffee Linked to Better Mood, Study Cautions on Withdrawal Relief

New Zealand Greenlights Restricted Psilocybin Therapy for Treatment-Resistant Depression

Single Psilocybin Dose Delivers Two-Year Relief From Depression and Anxiety in Cancer Patients

RFK Jr.'s Federal Commission on Childhood Health Raises Concerns Over Psychiatric Medication Access

Psilocybin Therapy Shows Promise for Millions with Depression

Massachusetts Voters to Decide on Psychedelic Legalization

High-Dose Psilocybin Shows Comparable Effect to Antidepressants in Treating Depression

FDA Declines MDMA for PTSD Treatment, Requests Further Trials

FDA Rejects MDMA for PTSD Treatment, Requests More Trials